Categories: Wire Stories

Korean AI-based Diagnostic Software Dr. Answer Helps Countries With a Shortage of Medical Professionals

-Saudi Arabia and Africa are in clinical verification of Dr. Answer while discussing its adoption


SEOUL, South Korea–(BUSINESS WIRE)–#AIDr. Answer, an innovative artificial intelligence (AI) based diagnostics application, is expected to significantly help countries with insufficient healthcare professionals make more efficient diagnosis.

Dr. Answer is a suite of AI-powered precision diagnostic software that supports healthcare. The suite is comprised of 21 AI-based software programs that assist diagnosis of 8 major diseases selected in consideration of mortality, the proportion of medical costs and public interest.

26 medical organizations developed Dr. Answer in collaboration with 22 information and communication technology companies in Korea for three years, and 38 medical organizations verified its stability and effectiveness in improving accuracy in diagnosis and reducing diagnosing time.

�Healthcare professionals at large general hospitals can easily make reference to opinions of other professionals when they involve in diagnosis and therapeutic decisions as a large number of professionals in diverse disciplines are working within the same hospitals. But a few medical professionals diagnose patients in many small hospitals or clinics where Dr. Answer can help professionals make an accurate diagnosis,” explained Kim Jong-jae, Director of Asan Institute for Life Sciences. “Dr. Answer can be usefully used in Europe, and countries with insufficient medical professionals such as Africa may achieve substantial outcomes when they use Dr. Answer,” added Kim.

Recognizing the excellence of Dr. Answer, hospitals affiliated with the Ministry of National Guard-Health Affairs of Saudi Arabia are currently conducting its clinical verification while discussing the possibility of its adoption.

Contacts

Dr. Answer

Lee Junyoung

+82-43-931-5500

leejy@nipa.kr

Alex

Recent Posts

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

GUANGDONG, CHINA AND BAGSVÆRD, DENMARK - Media OutReach Newswire - 24 March 2025 - The…

23 minutes ago

Contractor Sentiment Generally Positive as the Worst of Price Pressures Ease, According to Office Fit Out Vendors Across Asia Pacific

Six Greater China cities are ranked in the top 20 most expensive office fit out…

2 hours ago

SonicWall Partner Focus Drives Key Business Momentum in Transformational Year

SonicWall’s Wide-ranging Platform of Cybersecurity Solutions and Growth with Managed Security Services Providers (MSSPs) Underpin…

2 hours ago

Lenovo Hybrid AI Advantage with NVIDIA Boosts Business Productivity and Efficiency with New Scalable Agentic AI Solutions

New Lenovo agentic AI and hybrid AI factory platforms include NVIDIA Blackwell Ultra support and…

2 hours ago

CTF Life Introduces “GBA MediAccess” Outpatient Insurance Plan

Leverages CTF Group’s Diverse Conglomerate to Address Medical Needs of Families in the Guangdong–Hong Kong–Macau…

2 hours ago

Hang Lung Leads Industry Dialogue on Net Zero Transition with Groundbreaking Discussion Paper

Hang Lung presents an innovative in-depth analysis of its potential journey to net zero as…

3 hours ago